多中心、双盲、安慰剂对照、随机、平行组、非劣效性研究:比较基于黏弹性试验的目标导向氨甲环酸给药与预先氨甲环酸给药对心血管手术后出血的疗效(GDT试验)
这项多中心、双盲、安慰剂对照、随机、平行组、非劣效性试验计划在3家三级大学医院纳入764例心血管手术患者,按1:1随机分为预先给药组(Group-P)和目标导向给药组(Group-GDT)。主要结局为术后24小时出血量的组间比较,次要结局包括围术期输血、凝血指标、再次手术、血栓栓塞并发症、癫痫发作、院内死亡、纤溶表型和住院费用。
要点
- 试验假设基于ROTEM结果的选择性氨甲环酸给药在减少术后出血方面非劣效于预先给药。
- Group-P在麻醉诱导后给予氨甲环酸10 mg/kg和2 mg/kg/h,Group-GDT给予安慰剂。
- Group-GDT在体外循环脱机前和出血时检测ROTEM,A10-EXTEM≥40 mm且LI60-EXTEM≥85%给安慰剂,否则给氨甲环酸20 mg/kg。
核心结论
- 术后出血组间无差异将支持选择性策略在减少术后出血方面的非劣效性。
- Group-GDT可能减少血栓栓塞风险、癫痫发作和纤溶关闭,支持其在减少氨甲环酸所致不良事件及其管理成本方面的优越性。
研究设计与样本
- 非劣效性、随机、双盲、安慰剂对照、多中心试验,计划于2023年8月至2025年3月在3家三级大学医院进行。
- 计划纳入764例心血管手术患者,按1:1随机分配至预先给药组(Group-P)或目标导向策略组(Group-GDT)。
主要发现
- Group-P在麻醉诱导后给予氨甲环酸10 mg/kg和2 mg/kg/h,Group-GDT给予安慰剂。
- Group-GDT在体外循环脱机前和体外循环后明显出血时检测ROTEM,A10-EXTEM≥40 mm且LI60-EXTEM≥85%时给安慰剂,A10-EXTEM<40 mm或LI60-EXTEM<85%时给氨甲环酸20 mg/kg。
- 主要结局为术后24小时出血量的组间比较。
- 次要结局包括围术期输血、凝血指标、再次手术、血栓栓塞并发症、癫痫发作、院内死亡、纤溶表型和住院费用。
关键数值与推荐
- Group-GDT中,A10-EXTEM≥40 mm且LI60-EXTEM≥85%时给安慰剂,A10-EXTEM<40 mm或LI60-EXTEM<85%时给氨甲环酸20 mg/kg。
- Group-P中,氨甲环酸剂量为10 mg/kg和2 mg/kg/h。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid (TXA) effectively attenuates hyperfibrinolysis and preemptive administration has been employed to reduce bleeding and blood transfusions in various surgical settings. However, TXA administration could be associated with adverse effects, such as seizures and thromboembolic risks. While patients with fibrinolysis shutdown showed greater thromboembolic complications and mortality, TXA administration may aggravate the degree of shutdown in these patients. Selective TXA administration based on the results of rotational thromboelastometry (ROTEM) would be non-inferior to preemptive TXA administration in reducing postoperative bleeding and beneficial in reducing its risks in patients undergoing cardiovascular surgery. METHODS: This non-inferiority, randomized, double-blind, placebo-controlled, multicenter trial will be performed in 3 tertiary university hospitals from August 2023 to March 2025. Seven hundred sixty-four patients undergoing cardiovascular surgery will be randomly allocated to get TXA as a preemptive (Group-P) or goal-directed strategy (Group-GDT) in each institution (with a 1:1 allocation ratio). After anesthesia induction, TXA (10 mg/kg and 2 mg/kg/h) and a placebo are administered after anesthesia induction in Group-P and Group-GDT, respectively. ROTEM tests are performed immediately before weaning from CPB and at the considerable bleeding post-CPB period. After getting the test results, a placebo is administered in Group-P (regardless of the test results). In Group-GDT, placebo or TXA is administered according to the results: placebo is administered if the amplitude at 10 min (A10-EXTEM) is ≥ 40 mm and lysis within 60 min (LI60-EXTEM) of EXTEM assay is ≥ 85%, or TXA (20 mg/kg) is administered if A10-EXTEM is < 40 mm or LI60-EXTEM is < 85%. The primary outcome is inter-group comparisons of postoperative bleeding (for 24 h). The secondary measures include comparisons of perioperative blood transfusion, coagulation profiles, reoperation, thromboembolic complications, seizures, in-hospital mortality, fibrinolysis phenotypes, and hospital costs. DISCUSSION: The absence of inter-group differences in postoperative bleeding would support the selective strategy's non-inferiority in reducing postoperative bleeding in these patients. The possible reduction in thromboembolic risks, seizures, and fibrinolysis shutdown in Group-GDT would support its superiority in reducing TXA-induced adverse events and the cost of their management. TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov with the registration number NCT05806346 on March 28, 2023. TRIAL STATUS: recruiting. Issue date: 2023 March 28 (by Tae-Yop Kim, MD, PhD). The trial was registered in the clinical registration on March 28, 2023 (ClinicalTrials.gov, NCT05806346) and revised to the latest version of its protocol (version no. 8, August 26, 2024) approved by the institutional review boards (IRBs) of all 3 university hospitals (Konkuk University Medical Center, 2023-07-005-001, Asan Medical Center, 2023-0248, and Samsung Medical Center, SMC 2023-06-048-002). Its recruitment was started on August 1, 2023, and will be completed on December 31, 2024. Protocol amendment number: 08 (protocol version 08, August 26, 2024). Revision chronology: 2023 March 28:Original. 2023 April 10:Amendment No 01. The primary reason for the amendment is the modification of Arms (adding one arm for sub-group analyses) and Interventions, Outcome Measures, Study Design, Study Description, Study Status, Eligibility, and Study Identification. 2023 May 03:Amendment No 02. The primary reason for the amendment is to modify the Outcome Measures and update the study status. 2023 July 06:Amendment No 03. The primary reason for amendment is to update the chronological study status. 2023 July 07:Amendment No 04. The primary reason for the amendment is the modification of study information (the treatment category was changed to diagnostic, and Phase 4 was changed to not applicable) and a chronological update on the study status. 2023 September 12:Amendment No 06. The primary reason for the amendment is a chronological update in the study status and the inclusion of additional information regarding contacts/locations and oversight. 2023 December 29:Amendment No 07. The primary reason for the amendment is to modify the outcome measures (including detailed information on outcome measures, addition of extra secondary measures, and chronological updates in study status). 2024 August 26:Amendment No 08. The primary reason for the amendment is to add detailed descriptions regarding data handling and the names and roles of the participating institutions and to update the chronological process of the trial.
引用
- Nam JS, Oh CS, Kim JY, et al. A multi-center, double-blind, placebo-controlled, randomized, parallel-group, non-inferiority study to compare the efficacy of goal-directed tranexamic acid administration based on viscoelastic test versus preemptive tranexamic acid administration on postoperative bleeding in cardiovascular surgery (GDT trial). Trials. 2024. PMID: 39334224. doi:10.1186/s13063-024-08467-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。